A key challenge in life sciences is the detrimental effect of unplanned downtime and lost batches due to unanticipated equipment failure. Obtaining maximum value from assets makes a lot of sense to an asset-intensive organization, and the Pharmaceutical Industry is not the exception. Today, we have at our reach many resources to design and implement a robust maintenance and reliability strategy supporting the particular needs of the pharma industry. Asset and Risk Management principles and maintenance and reliability engineering concepts constitute the backbone of an effective maintenance program. But unfortunately, that may not be enough in the pharma industry where Good Manufacturing Practice (GMP), a system for ensuring that products are consistently produced and controlled according to quality standards, quality assurance, and quality control are a big part of manufacturing.